Serum IGFBP‐3 levels in CRC patients were significantly lower than those of controls (4.68 [3.56, 5.77] vs 5.44 [4.77, 6.10] μg/mL, P = 0.03; Figure 1A); serum CEA levels in CRC patients were higher than those of controls (2.6 [1.6, 6.3] vs (1.8 [1.4, 2.5] ng/mL, P = 0.04; Figure 1B). The gene discussed is CEACAM5; the disease is colorectal carcinoma.